FDA approval of MIMRYLO triggers milestone payments to Protagonist Therapeutics
The approval validates Protagonist's peptide platform and brings milestone revenue alongside its quarterly update.
Read at Stock Titan →Full coverage · 7 outlets
- Stock Titan · lead
- The Columbus DispatchProtagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- Simply Wall StProtagonist Therapeutics (PTGX) Wins FDA Nod for MIMRYLO and a $275 Million Milestone
- MedCity NewsFirst-in-Class Takeda, Protagonist Drug Lands FDA Approval in Rare Blood Disorder
- scanx.tradeTakeda wins FDA approval for MIMRYLO, triggers $275m payout to Protagonist
- ACCESS NewswireProtagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera
- YahooProtagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Update